Anna Berkenblit compensation by year
ImmunoGen Summary Compensation Table · all 3 fiscal years held| Component | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Salary | $480,233 | $496,237 | $512,302 |
| Option awards | $958,326 | $1,863,213 | $1,172,444 |
| Non-equity incentive | $152,131 | $141,368 | $194,616 |
| All other | $9,372 | $9,672 | $10,122 |
| Total | $1,600,062 | $2,510,490 | $1,889,484 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ImmunoGen, Inc. DEF 14A filed April 26, 2023, accession 0001558370-23-006874, and prior-year filings. Open the filing on EDGAR.
How this page was built: the ImmunoGen, Inc. filed document, accession 0001558370-23-006874. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 23,125 | — | $5.25 |
| Option | 92,625 | — | $4.55 |
| Option | 55,575 | — | $4.55 |
| Option | 311,700 | — | $5.32 |
| Option | 158,635 | — | $7.69 |
Per the Outstanding Equity Awards at Fiscal Year-End table in ImmunoGen, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments ImmunoGen discloses, by trigger · FY2022| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $514,857 | — | $39,399 | $760,199 |
| Change in control and involuntary termination | $1,081,200 | $60,762 | $59,099 | $1,241,061 |
Per the Potential Payments Upon Termination or Change in Control table in ImmunoGen, Inc.'s FY2022 proxy. Estimates as the company printed them; a dash means it printed no figure.
ImmunoGen’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Mark Enyedy | President and Chief Executive Officer | $5,422,421 |
| Michael Vasconcelles | Executive Vice President Research, Development and Medical Affairs | $3,814,652 |
| Anna Berkenblit · this page | Senior Vice President and Chief Medical Officer | $1,889,484 |
| Stacy Coen | Senior Vice President and Chief Business Officer | $1,838,354 |
| Susan Altschuller | Former Senior Vice President and Chief Financial Officer | $1,791,733 |
| Renee Lentini | Vice President and Interim Chief Financial Officer | $965,989 |
The full ImmunoGen compensation record
free company briefThis page is one person within ImmunoGen's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the ImmunoGen proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ImmunoGen's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.